Penthrox submitted for Regulatory Approval in 22 European Countries
29 November 2016
PENTHROX SUBMITTED FOR REGULATORY APPROVAL IN 22 EUROPEAN COUNTRIES
Medical Developments International Limited (ASX:MVP) is delighted to confirm that its partner in Western Europe, Mundipharma International Corporation Limited (Mundipharma) submitted an application on 28 November 2016 to the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) under the Decentralised Procedure to have Penthrox approved for sale in:
Austria, Denmark, Italy, Poland, Spain, Bulgaria, Estonia, Latvia, Portugal, Sweden, Croatia, Finland, Lithuania, Romania, Cyprus, Germany, Luxembourg, Slovakia, Czech Republic, Iceland Norway and Slovenia.
For details relating to the full ASX release, please click on the following link: European-Regulatory-Submission